Legal & General Group’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $47.4K | Buy |
+7,402
| New | +$47.4K | ﹤0.01% | 2718 |
|
|
2024
Q2 | – | Sell |
-32,854
| Closed | -$93.3K | – | 3416 |
|
|
2024
Q1 | $93.3K | Sell |
32,854
-6,812
| -17% | -$19.3K | ﹤0.01% | 2740 |
|
|
2023
Q4 | $584K | Buy |
39,666
+7,564
| +24% | +$111K | ﹤0.01% | 2395 |
|
|
2023
Q3 | $588K | Buy |
32,102
+3,586
| +13% | +$65.7K | ﹤0.01% | 2371 |
|
|
2023
Q2 | $615K | Buy |
28,516
+1,464
| +5% | +$31.6K | ﹤0.01% | 2393 |
|
|
2023
Q1 | $794K | Buy |
27,052
+22,029
| +439% | +$646K | ﹤0.01% | 2203 |
|
|
2022
Q4 | $186K | Buy |
5,023
+1,562
| +45% | +$57.7K | ﹤0.01% | 2639 |
|
|
2022
Q3 | $97K | Buy |
3,461
+2,237
| +183% | +$62.7K | ﹤0.01% | 2835 |
|
|
2022
Q2 | $24K | Buy |
1,224
+319
| +35% | +$6.26K | ﹤0.01% | 3168 |
|
|
2022
Q1 | $12K | Buy |
+905
| New | +$12K | ﹤0.01% | 3354 |
|